Home LiteratureArticle Details
PMID: 2994737 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Isolation and construction of mutants of the G4 minus strand origin: analysis of their in vivo activity.

Biochimica et biophysica acta ·Vol. 826 ·No. 1 ·1985-10-03 ·Pages 30-7

Sakai H, Godson GN

Abstract

An active, rifampicin-resistant primase-dependent bacteriophage G4 origin of complementary DNA strand synthesis has been cloned as a 274 bp fragment into the filamentous phase M13 and its secondary structure altered by deletion and insertion. It has been found that the entire 136 bp G4 intergenic region containing the secondary structure loops I and III is necessary for rifampicin-resistant conversion of SS----RF DNA in vivo. The secondary structures, however, can be widely separated by insertion between them of both random DNA sequences, and sequences that form strong additional secondary structure configurations and the origins still retain activity. Primase therefore probably recognises two DNA domains on loops I and III, the physical separation of which is not important.

MeSH Terms
Base Sequence Cloning, Molecular Coliphages/drug effects,genetics DNA Restriction Enzymes DNA, Viral/genetics Drug Resistance, Microbial Escherichia coli/drug effects,genetics Mutation Nucleic Acid Conformation Plasmids Rifampin/pharmacology
Chemicals
DNA, Viral DNA Restriction Enzymes Rifampin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sakai H
Godson G N
Article Info
Journal
Biochimica et biophysica acta
Abbr.
Biochim Biophys Acta
ISSN
0006-3002
Published
1985-10-03
Pages
30-7
Language
English
Region
Netherlands
NLM ID
0217513
Subset
IM
Grants
NIAID NIH HHS · NIAID# 7-1142-996 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com